AVALANCHE BIOTECHNOLOGIES IN's ticker is AAVL and the CUSIP is 05337G107. A total of 58 filers reported holding AVALANCHE BIOTECHNOLOGIES IN in Q3 2014. The put-call ratio across all filers is - and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2016 | $4,318,000 | -45.0% | 835,270 | +1.2% | 0.00% | -50.0% |
| Q4 2015 | $7,857,000 | +7.5% | 825,304 | -6.9% | 0.00% | 0.0% |
| Q3 2015 | $7,308,000 | -46.4% | 886,901 | +5.6% | 0.00% | -33.3% |
| Q2 2015 | $13,635,000 | -36.8% | 839,620 | +57.8% | 0.00% | -40.0% |
| Q1 2015 | $21,558,000 | -12.3% | 532,023 | +16.9% | 0.01% | -16.7% |
| Q4 2014 | $24,576,000 | +322.9% | 455,108 | +167.8% | 0.01% | +200.0% |
| Q3 2014 | $5,811,000 | – | 169,950 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| VHCP Management, LLC | 1,102,735 | $10,498,000 | 6.34% |
| VHCP Management II, LLC | 280,000 | $2,666,000 | 2.19% |
| DAFNA Capital Management LLC | 140,600 | $1,339,000 | 1.19% |
| Wildcat Capital Management, LLC | 235,264 | $2,240,000 | 0.63% |
| CADIAN CAPITAL MANAGEMENT, LP | 1,529,537 | $14,561,000 | 0.52% |
| Rhenman & Partners Asset Management AB | 154,006 | $1,466,000 | 0.22% |
| Numeric Investors LLC | 1,195,235 | $11,379,000 | 0.12% |
| SABBY MANAGEMENT, LLC | 195,132 | $1,858,000 | 0.10% |
| LANDSCAPE CAPITAL MANAGEMENT, L.L.C. | 73,069 | $696,000 | 0.09% |
| OXFORD ASSET MANAGEMENT LLP | 362,776 | $3,454,000 | 0.08% |